Moreover, clinical studies in primary breast carcinoma, head and neck squamous cell carcinoma, and CRC suggest that TP53 inactivation or deletion induces inflammation (Yin et al., 1993; Brentnall et al., 1994; Hussain et al., 2000; Linderholm et al., 2000; Lee et al., 2007). This evidence concerns the gene TP53 and breast carcinoma.